ArticleCureus2024
Coexistence of Monoclonal Gammopathy and Hemolysis in Chronic Lymphocytic Leukemia: Unveiling a Rare Case.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In B-cell malignancies, there is a periodic presence of monoclonal gammopathies. In a notable multitude of cases with chronic lymphocytic leukemia (CLL), a cluster of antigen-inciting B-cells sometimes shows the presence of monoclonal gammopathy and autoimmune hemolysis simultaneously. The detection of monoclonal proteins or light chains in urine and/or serum is significantly increased in cases of CLL and can be identified using highly sensitive laboratory methods, such as serum protein electrophoresis. Hemolysis in these patients can be detected by the direct Coombs test (DCT). Several scientific research data indicate that the findings of hemolysis and the presence of monoclonal proteins have an adverse impact on the survival of patients. Nevertheless, there is no perspicuous proof to indicate the prognostic importance of hemolysis and monoclonal gammopathy in patients with CLL, even though monoclonal proteins and hemolysis in CLL generally occur at prevalences of 60%-80% and 5%-10%, respectively, very few cases have been reported in the literature. Owing to the peculiarity, we report a case of CLL diagnosed in 2023. The 66-year-old woman had developed the progressive disease along with the existence of monoclonal gammopathy and hemolysis. Although the manifestation of both findings could be due to the use of highly sensitive methods, it may also be attributable to an autoimmune process or progression from similar or distinct B-cell clones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.